{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=56", "query": { "condition": "Relapse Leukemia", "page": 56 }, "page_size": 10 }, "pagination": { "page": 56, "page_size": 10, "total_count": 1826, "total_pages": 183, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=57&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=55&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T00:38:35.484Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00024440", "title": "Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "oblimersen sodium", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genta Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 1, "location_summary": "Berkeley Heights, New Jersey", "locations": [ { "city": "Berkeley Heights", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024440" }, { "nct_id": "NCT02477878", "title": "Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Lymphoma", "Multiple Myeloma", "Hematologic Neoplasms" ], "interventions": [ { "name": "BPX-501", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2016-07", "completion_date": "2033-01", "has_results": false, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Buffalo", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02477878" }, { "nct_id": "NCT00006240", "title": "Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "oral sodium phenylbutyrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": "2001-08", "has_results": false, "last_update_posted_date": "2015-04-28", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 4, "location_summary": "Bethesda, Maryland • New York, New York • Pittsburgh, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006240" }, { "nct_id": "NCT01041508", "title": "Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia Lymphoblastic, Acute", "Acute Myeloid Leukemia", "Neoplasm Recurrent" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Stem Cell Transplantation", "type": "OTHER" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 18, "start_date": "2010-01-29", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2024-02-01", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 6, "location_summary": "Los Angeles, California • Columbus, Ohio • Portland, Oregon + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01041508" }, { "nct_id": "NCT00462189", "title": "Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Hairy Cell Leukemia", "HCL" ], "interventions": [ { "name": "Immunotoxin therapy", "type": "DRUG" }, { "name": "CAT-8015 Immunotoxin", "type": "DRUG" }, { "name": "Biological therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Cambridge Antibody Technology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2007-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-04-18", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 3, "location_summary": "Stanford, California • Chicago, Illinois • Bethesda, Maryland", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462189" }, { "nct_id": "NCT04881240", "title": "Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia, Refractory", "Pediatric ALL" ], "interventions": [ { "name": "CD19-CAR(Mem) T-cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "CliniMACS", "type": "DEVICE" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 60, "start_date": "2024-02-14", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04881240" }, { "nct_id": "NCT06834282", "title": "CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "CER-1236", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CERo Therapeutics Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 18, "start_date": "2025-04-07", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 5, "location_summary": "Sacramento, California • Denver, Colorado • Nashville, Tennessee + 2 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06834282" }, { "nct_id": "NCT00900068", "title": "Blood Samples From Patients on a Clinical Trial to CINV During HSCT", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Nausea and Vomiting", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 9, "start_date": "2008-08", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900068" }, { "nct_id": "NCT00014391", "title": "Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "palivizumab", "type": "BIOLOGICAL" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1999-02", "completion_date": "2001-10", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014391" }, { "nct_id": "NCT00004862", "title": "Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "oblimersen sodium", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 24, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-11-11T00:38:35.484Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004862" } ] }